Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT07222800, led by Pfizer, and recruiting on the registry. Official title: An interventional, phase 3, double-blind, randomised study to evaluate the efficacy and safety of PF-08634404 in combination with chemotherapy versus bevacizumab in combination with chemotherapy in treatment-naïve participants with metastatic colorectal cancer. Planned enrolment is 800 participants (estimated). The study started in 2025-12-11 and primary completion is expected in 2030-03-29. No results have been posted on ClinicalTrials.gov.